NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
Advanced Micro Devices
AMD
5
Super Micro Computer
SMCI
US Stock MarketDetailed Quotes
ALNY Alnylam Pharmaceuticals
- 246.750
- +9.650+4.07%
Close Feb 28 16:00 ET
- 246.750
- 0.0000.00%
Post 20:01 ET
31.94BMarket Cap-113.19P/E (TTM)
249.340High236.500Low1.18MVolume236.500Open237.100Pre Close288.76MTurnover0.95%Turnover RatioLossP/E (Static)129.46MShares304.39052wk High476.35P/B30.71BFloat Cap141.97552wk Low--Dividend TTM124.46MShs Float304.390Historical High--Div YieldTTM5.42%Amplitude3.650Historical Low244.996Avg Price1Lot Size
Alnylam Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 22.97%2.25B | 34.90%593.17M | -33.26%500.92M | 107.00%659.83M | 54.82%494.33M | 76.23%1.83B | 31.25%439.72M | 183.96%750.53M | 41.78%318.75M | 49.72%319.29M |
| Operating revenue | 22.97%2.25B | 34.90%593.17M | -33.26%500.92M | 107.00%659.83M | 54.82%494.33M | 76.23%1.83B | 31.25%439.72M | 183.96%750.53M | 41.78%318.75M | 49.72%319.29M |
| Cost of revenue | 4.18%323.37M | 19.75%102.82M | 1.89%85.91M | -19.56%68.67M | 20.24%65.98M | 83.87%310.41M | 67.48%85.86M | 105.05%84.31M | 109.20%85.37M | 54.01%54.87M |
| Gross profit | 26.81%1.92B | 38.57%490.35M | -37.71%415.01M | 153.30%591.15M | 62.00%428.36M | 74.75%1.52B | 24.70%353.86M | 198.50%666.22M | 26.83%233.38M | 48.86%264.42M |
| Operating expense | 16.76%2.1B | 26.63%595.51M | 8.75%491.92M | 17.12%542.54M | 13.90%471.79M | 8.85%1.8B | -0.45%470.26M | -6.00%452.35M | 23.30%463.22M | 27.70%414.23M |
| Selling and administrative expenses | 22.61%975.53M | 49.07%295.34M | 10.95%220.99M | 15.70%248.4M | 14.78%210.8M | 3.24%795.65M | -5.81%198.12M | -15.55%199.18M | 26.30%214.69M | 18.90%183.66M |
| -General and administrative expense | 22.61%975.53M | 49.07%295.34M | 10.95%220.99M | 15.70%248.4M | 14.78%210.8M | 3.24%795.65M | -5.81%198.12M | -15.55%199.18M | 26.30%214.69M | 18.90%183.66M |
| Research and development costs | 12.13%1.13B | 10.30%300.17M | 7.01%270.93M | 18.35%294.14M | 13.20%261M | 13.75%1B | 3.86%272.14M | 3.18%253.18M | 20.81%248.53M | 35.71%230.57M |
| Operating profit | 37.31%-176.89M | 9.66%-105.16M | -135.96%-76.91M | 121.15%48.61M | 71.01%-43.44M | 64.06%-282.18M | 38.28%-116.4M | 182.88%213.87M | -19.90%-229.83M | -2.10%-149.81M |
| Net non-operating interest income expense | 22.58%-19.87M | -753.22%-7.95M | 59.22%-2.23M | 54.51%-4.08M | 45.55%-5.61M | 80.44%-25.66M | 94.11%-932K | 83.56%-5.47M | 77.99%-8.96M | 75.09%-10.3M |
| Non-operating interest income | 27.66%121.99M | 2.02%31.02M | 26.43%32.15M | 38.47%29.18M | 58.91%29.65M | 285.20%95.56M | 116.00%30.41M | 225.13%25.43M | 1,009.79%21.08M | 1,743.38%18.66M |
| Non-operating interest expense | 17.02%141.86M | 24.36%38.97M | 11.27%34.38M | 10.73%33.26M | 21.75%35.25M | -22.28%121.22M | 4.76%31.34M | -24.81%30.89M | -29.51%30.04M | -31.65%28.96M |
| Other net income (expense) | -43.72%-180.62M | -297.26%-80.85M | 48.79%-29.53M | -57.28%-55.71M | -18.68%-14.54M | 40.37%-125.68M | -691.56%-20.35M | 49.70%-57.66M | 16.22%-35.42M | 76.10%-12.26M |
| Gain on sale of security | -61.01%-173.79M | -215.37%-70.44M | 21.26%-37.84M | -97.84%-57.01M | 2.63%-8.51M | 15.65%-107.94M | -30.71%-22.34M | -45.91%-48.05M | ---28.82M | 80.56%-8.74M |
| Special income (charges) | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | 61.49%-6.83M | -624.70%-10.41M | 186.52%8.31M | 119.75%1.3M | -71.62%-6.04M | -185.96%-17.74M | -86.33%1.98M | -87.63%-9.61M | 84.38%-6.6M | 44.45%-3.52M |
| Income before tax | 12.95%-377.38M | -40.87%-193.96M | -172.09%-108.66M | 95.93%-11.17M | 63.11%-63.59M | 61.53%-433.52M | 33.49%-137.69M | 137.13%150.74M | 0.17%-274.21M | 27.99%-172.36M |
| Income tax | -1,575.36%-99.22M | -60,315.85%-110.2M | -2.71%2.91M | 215.26%5.72M | 35.02%2.35M | 61.54%6.73M | -61.23%183K | 13,091.30%2.99M | -33.49%1.82M | 76.55%1.74M |
| Net income | 36.82%-278.16M | 39.24%-83.76M | -175.51%-111.57M | 93.88%-16.89M | 62.13%-65.94M | 61.08%-440.24M | 33.55%-137.87M | 136.40%147.75M | 0.50%-276.02M | 27.56%-174.1M |
| Net income continuous Operations | 36.82%-278.16M | 39.24%-83.76M | -175.51%-111.57M | 93.88%-16.89M | 62.13%-65.94M | 61.08%-440.24M | 33.55%-137.87M | 136.40%147.75M | 0.50%-276.02M | 27.56%-174.1M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 36.82%-278.16M | 39.24%-83.76M | -175.51%-111.57M | 93.88%-16.89M | 62.13%-65.94M | 61.08%-440.24M | 33.55%-137.87M | 136.40%147.75M | 0.50%-276.02M | 27.56%-174.1M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 36.82%-278.16M | 39.24%-83.76M | -175.51%-111.57M | 93.88%-16.89M | 62.13%-65.94M | 61.08%-440.24M | 33.55%-137.87M | 136.40%147.75M | 0.50%-276.02M | 27.56%-174.1M |
| Basic earnings per share | 38.07%-2.18 | 40.91%-0.65 | -173.73%-0.87 | 94.12%-0.13 | 62.86%-0.52 | 62.15%-3.52 | 34.52%-1.1 | 135.54%1.18 | 3.49%-2.21 | 30.00%-1.4 |
| Diluted earnings per share | 38.07%-2.18 | 40.91%-0.65 | -175.65%-0.87 | 94.12%-0.13 | 62.86%-0.52 | 62.15%-3.52 | 34.52%-1.1 | 134.64%1.15 | 3.49%-2.21 | 30.00%-1.4 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |